Towards a better registration of neuroendocrine neoplasms: The results of the Italian retrospective population-based study.

IF 2 4区医学 Q3 ONCOLOGY

Tumori Pub Date : 2025-02-26 DOI:10.1177/03008916251317128

Annalisa Trama, Francesco Cuccaro, Domenico Damiani, Alice Bernasconi, Francesco Panzuto, Nicola Fazio, Simona Carone, Maria Giovanna Burgio Lo Monaco, Rossella Bruni, Adele Caldarella, Annalisa Roselli, Barbara Cortini, Rosalba Amodio, Walter Mazzucco, Silvia Leite, Chiara Lupi, Maddalena Baracco, Eva Carpin, Antonella Dal Cin, Annarita Fiore, Laura Memo, Stefano Guzzinati, Antonietta Alfia Maria Torrisi, Antonina Torrisi, Margherita Ferrante, Maria Teresa Pesce, Alessandra Sessa, Antonietta Minichino, Nadia Di Pascale, Maria Francesca Vitale, Mario Fusco, Ilaria Girolami, Massimo Milione, Fabrizio Stracci

{"title":"Towards a better registration of neuroendocrine neoplasms: The results of the Italian retrospective population-based study.","authors":"Annalisa Trama, Francesco Cuccaro, Domenico Damiani, Alice Bernasconi, Francesco Panzuto, Nicola Fazio, Simona Carone, Maria Giovanna Burgio Lo Monaco, Rossella Bruni, Adele Caldarella, Annalisa Roselli, Barbara Cortini, Rosalba Amodio, Walter Mazzucco, Silvia Leite, Chiara Lupi, Maddalena Baracco, Eva Carpin, Antonella Dal Cin, Annarita Fiore, Laura Memo, Stefano Guzzinati, Antonietta Alfia Maria Torrisi, Antonina Torrisi, Margherita Ferrante, Maria Teresa Pesce, Alessandra Sessa, Antonietta Minichino, Nadia Di Pascale, Maria Francesca Vitale, Mario Fusco, Ilaria Girolami, Massimo Milione, Fabrizio Stracci","doi":"10.1177/03008916251317128","DOIUrl":null,"url":null,"abstract":"Background: The increasing incidence, rapidly evolving classification, rarity and heterogeneity of neuroendocrine neoplasms (NENs) pose challenges to NEN registration including difficulty in distinguishing neuroendocrine carcinoma (NEC) and neuroendocrine tumours (NETs). Thus, in Italy a higher NEC incidence was reported. Focusing on gastroenteropancreatic (GEP) NEN, we aimed to review GEP NEN, and in particular cases of neuroendocrine carcinoma, not otherwise specified (NOS) and estimate the incidence of NEN, NET and NEC of the GEP.Methods: We launched a pilot study examining cases of neuroendocrine carcinomas NOS (ICD-O3 code 8246) of GEP incidents in the years 2012-2020. Cancer registries (CRs) reviewed information included in the pathology report regarding differentiation and tumour cells proliferation to decide whether to confirm the case as neuroendocrine carcinoma NOS or register it as NET or NEC. After the review, we estimated the GEP NEN, NET and NEC incidence.Results: Nine CRs contributed to the pilot study. After review, in all CRs, only 31% of GEP NOS neuroendocrine carcinomas were confirmed; 50% were recoded as NETs, and approximately 17% of cases were non-NENs. The IR of GEP NENs was 2.99/100,000, and the incidence of NETs was higher than that of NECs.Conclusion: After the review, the incidence of GEP NEN, NET and NEC in the eight Italian CRs involved was comparable to that reported in other European countries.Impact: Our results confirmed that heterogeneity of cancer registries in the registration of NEN requires collaborative work to define and promote a standard definition to be extended to all Italian registries.","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916251317128"},"PeriodicalIF":2.0000,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumori","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03008916251317128","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The increasing incidence, rapidly evolving classification, rarity and heterogeneity of neuroendocrine neoplasms (NENs) pose challenges to NEN registration including difficulty in distinguishing neuroendocrine carcinoma (NEC) and neuroendocrine tumours (NETs). Thus, in Italy a higher NEC incidence was reported. Focusing on gastroenteropancreatic (GEP) NEN, we aimed to review GEP NEN, and in particular cases of neuroendocrine carcinoma, not otherwise specified (NOS) and estimate the incidence of NEN, NET and NEC of the GEP.

Methods: We launched a pilot study examining cases of neuroendocrine carcinomas NOS (ICD-O3 code 8246) of GEP incidents in the years 2012-2020. Cancer registries (CRs) reviewed information included in the pathology report regarding differentiation and tumour cells proliferation to decide whether to confirm the case as neuroendocrine carcinoma NOS or register it as NET or NEC. After the review, we estimated the GEP NEN, NET and NEC incidence.

Results: Nine CRs contributed to the pilot study. After review, in all CRs, only 31% of GEP NOS neuroendocrine carcinomas were confirmed; 50% were recoded as NETs, and approximately 17% of cases were non-NENs. The IR of GEP NENs was 2.99/100,000, and the incidence of NETs was higher than that of NECs.

Conclusion: After the review, the incidence of GEP NEN, NET and NEC in the eight Italian CRs involved was comparable to that reported in other European countries.

Impact: Our results confirmed that heterogeneity of cancer registries in the registration of NEN requires collaborative work to define and promote a standard definition to be extended to all Italian registries.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Tumori 医学-肿瘤学

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

6 months

期刊介绍： Tumori Journal covers all aspects of cancer science and clinical practice with a strong focus on prevention, translational medicine and clinically relevant reports. We invite the publication of randomized trials and reports on large, consecutive patient series that investigate the real impact of new techniques, drugs and devices inday-to-day clinical practice.